Latest News - Shire

Tuesday, January 09, 2018 | Earnings & Financials, Shire

Shire to Operate as Two Business Units Focused on Neuroscience, Rare Diseases

Shire said that following the first stage of its strategic review, it will separate its operations into two divisions, namely neuroscience and rare diseases. CEO Flemming Ornskov stated "our new …

Read the full story

Wednesday, January 03, 2018 | Dry Eye, Shire

Xiidra Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease

Shire announced that Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adults, has been approved …

Read the full story

Wednesday, December 20, 2017 | Acquisitions/Mergers, Shire

Report: With M&A Cash Likely On Its Way to U.S., Shire's Drawing Pharma Suitors

Will Shire investors get a Christmas present in the form of a buyout? As Republicans put the final touches on their new tax plan, so too are large pharma companies circling Shire for a potential acq…

Read the full story

Friday, December 01, 2017 | Management/Leadership, Shire

Shire Appoints Andreas Busch, PhD, as Head of Research and Development and Chief Scientific Officer

Shire announced that Andreas (Andy) Busch, PhD, will join Shire as Executive Vice President, Head of Research and Development, and Chief Scientific Officer, and will become a member of the company'…

Read the full story

Monday, October 02, 2017 | Corporate Lawsuits, Dry Eye, Allergan, Shire

Shire Alleges Allergan Blocked Drug From Medicare Contracts

Shire filed an antitrust suit against Allergan alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug, ac…

Read the full story

Tuesday, August 15, 2017 | Dry Eye, Shire

Shire Applies for European Approval for Dry Eye Drug Lifitegrast

Shire announced that it has submitted a Marketing Authorization Application (MAA) in the UK for lifitegrast for the treatment of dry eye disease. The application, submitted on August 7, 2017, has been…

Read the full story

Friday, July 07, 2017 | Shire

Shire Will Cut US Locations and Move HQ in Consolidation Push

Shire has decided to concentrate its U.S. operations into two main sites in Massachusetts -- Cambridge and Lexington -- in a move that will probably lead to the closure of some sites, according to a r…

Read the full story

Tuesday, June 20, 2017 | Management/Leadership, Shire

Shire Announces Appointment of John Snisarenko to Group VP & Head of Ophthlamics

Shire has announced the appointment of John Snisarenko as Group Vice President & Head of Ophthalmics US Franchise. Mr. Snisarenko replaces Robert Dempsey, who has taken on a leadership role on Shi…

Read the full story

Monday, May 01, 2017 | Dry Eye, Partnerships, Parion Sciences, Shire

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Shire and Parion Sciences announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investi…

Read the full story

Monday, April 24, 2017 | Clinical Trials, Shire

Shire Initiates Phase 3 Clinical Trial Program for SHP640 in Infectious Conjunctivitis for Adults and Children

Shire announced the initiation of the phase 3 clinical development program for SHP640, a combination broad spectrum antiseptic and corticosteroid in development for the treatment of infectious conjunc…

Read the full story

Wednesday, March 22, 2017 | Management/Leadership, Shire

Joe Boyd Joins Shire as Director, Market Development, Ophthalmics

Shire has announced that Joe Boyd has joined the Ophthalmics team as Director, Market Development. In this role, Mr. Boyd will work closely with thought leaders, key opinion leaders, and teaching inst…

Read the full story

Friday, February 17, 2017 | Dry Eye, Earnings & Financials, Shire

Shire Provides Update on Early Xiidra Sales

As part of its fourth quarter and full-year earnings release on Thursday, Shire provided information about the early sales of its dry eye disease drug Xiidra (lifitegrast), which was launched in Augus…

Read the full story

Monday, January 30, 2017 | Management/Leadership, Shire

Shire Names Sushanta Mallick as VP, Global Development Lead for Ophthalmics

Shire has named Sushanta Mallick to its ophthalmics team as vice president and global development lead for clinical development, ophthalmics, according to a company announcement. Mr. Mallick, a former…

Read the full story

Tuesday, January 17, 2017 | Management/Leadership, Shire

Sushanta Mallick Joins Shire Ophthalmic as VP & Global Development Lead for Clinical Development

Shire has annoucned that Sushanta Mallick has joined the ophthalmics team as Vice President & Global Development Lead for Clinical Development, Ophthalmics. Mr. Mallick has more than 20 years o…

Read the full story

Monday, October 17, 2016 | Medical Studies, Shire

Shire Survey: Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease

Shire announced that in results released today from a new national survey, nearly nine in 10 eye care professionals (ECPs) (89%) believe our modern, multi-screen lifestyle (i.e., everyday use of mobil…

Read the full story
Load More